Market closed
Liquidia/$LQDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Ticker
$LQDA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
170
Website
Liquidia Metrics
BasicAdvanced
$1.2B
-
-$1.66
0.22
-
Price and volume
Market cap
$1.2B
Beta
0.22
52-week high
$16.81
52-week low
$8.26
Average daily volume
1.1M
Financial strength
Current ratio
4.43
Quick ratio
4.289
Long term debt to equity
134.529
Total debt to equity
158.382
Interest coverage (TTM)
-9.71%
Management effectiveness
Return on assets (TTM)
-43.49%
Return on equity (TTM)
-209.35%
Valuation
Price to revenue (TTM)
77.156
Price to book
15.04
Price to tangible book (TTM)
16.55
Price to free cash flow (TTM)
-10.6
Growth
Revenue change (TTM)
-19.97%
Earnings per share change (TTM)
37.16%
3-year revenue growth (CAGR)
2.88%
3-year earnings per share growth (CAGR)
33.26%
What the Analysts think about Liquidia
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Liquidia Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Liquidia Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Liquidia News
AllArticlesVideos
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·3 weeks ago
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·3 weeks ago
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Liquidia stock?
Liquidia (LQDA) has a market cap of $1.2B as of April 19, 2025.
What is the P/E ratio for Liquidia stock?
The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of April 19, 2025.
Does Liquidia stock pay dividends?
No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Liquidia dividend payment date?
Liquidia (LQDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Liquidia?
Liquidia (LQDA) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.